

Publikationen 2002

Originalpublikationen in wissenschaftlichen Zeitschriften

1. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, Hirschel B, Boggian K, Chave JP, Opravil M, Weber R, Rickenbach M, Telenti A, and the Swiss HIV Cohort Study. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral therapy. The Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 2002;31:50-5.
2. Blanc DS, Pittet D, Ruef C, Widmer AF, Mühlemann K, Petignat C, Harbarth S, Auckenthaler R, Bille J, Frei R, Zbinden R, Peduzzi R, Gaia V, Khamis H, Bernasconi E, Francioli P. Epidemiology of methicillin-resistant *Staphylococcus aureus*: results of a nation-wide survey in Switzerland. *Swiss Medical Weekly* 2002;132:223-229.
3. Blanc DS, Pittet D, Ruef C, Widmer AF, Mühlemann K, Petignat C, Harbarth S, Auckenthaler R, Bille J, Frei R, Zbinden R, Moreillon P, Sudre P, Francioli P. Molecular epidemiology of predominant clones and sporadic strains of methicillin resistant *Staphylococcus aureus* in Switzerland and comparison with European epidemic clones. *Clin Microbiol Infect* 2002;8:419-426.
4. Bucher HC, Bichsel M, Taffé P, Furrer HJ, Telenti A, Hirschel B, Weber R, Bernasconi E, Vernazza P, Minder C, Battegay M, for the Swiss HIV Cohort Study. Ritonavir plus Saquinavir versus single protease inhibitor therapy in protease inhibitor-naïve HIV-infected patients. The Swiss HIV Cohort Study. *HIV Medicine* 2002;3:247-253.
5. Chang T, Gordon CJ, Roscic-Mrkic B, Power C, Proudfoot AEI, Moore JPM, Trkola A. Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity. *J Virol* 2002;76:2245-2254.
6. Colombo C, Giger H, Grote J, Deplazes C, Pletscher W, Lüthy R, Ruef C. Impact of teaching interventions on nurses compliance with hand disinfection. *J Hosp. Infect* 2002;51:69-72.
7. Ebnöther C, Altwegg M, Gottschalk J, Seebach J.D, Kronenberg A. *Aerococcus urinae* endocarditis: case report and review of the literature. *Infection* 2002;30:310-13.
8. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA, and the ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002;360:119-129.
9. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, for the Swiss HIV Cohort Study. Response to antiretroviral

treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. *Lancet* 2002;359:30-36.

10. Fischer M, Wong JK, Russenberger D, Joos B, Opravil M, Hirschel B, Trkola A, Kuster H, Weber R, Günthard HF, for the Swiss HIV Cohort Study. Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. *Antiviral Therapy* 2002;7:91-103.
11. Fleisch F, Zimmermann-Baer U, Zbinden R, Bischoff G, Arlettaz R, Waldvogel K, Nadal D, Rued C. Three consecutive outbreaks of *Serratia marcescens* in an neonatal intensive care unit. *Clin Infect Dis* 2002;34:767-773.
12. Greub G, Cozzi A, Ledergerber B, Staszewski S, Perrin L, Miller V, Francioli P, Furrer H, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Hirschel B, Philipps A, Telenti A for the Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study (SHCS). Intermittent and sustained low level HIV viral rebound in patients receiving potent antiretroviral therapy. *AIDS* 2002;16(14):1967-1969.
13. Hersberger M, Marti-Jaun J, Hänseler E and Speck RF. Rapid detection of the CCR2-V64I, CCR5-A59029G and SDF1-G801A polymorphisms by tetra-primer PCR. *Clin Biochem* 2002;35(5):399.
14. Hirschel B, Flepp M, Bucher HC, Zellweger C, Telenti A, Wagners T, Bernasconi E, Ledergerber B, and the Swiss HIV Cohort. Switching from protease inhibitors to efavirenz: Differences in efficacy and tolerance among risk groups. A case-control study from the Swiss HIV Cohort. *AIDS* 2002;16:381-385.
15. Keppler OT, Welte FJ, Ngo T, Patton KS, Tsou C, Abbey NW, Sharkey ME, You Y, Littman D, Stevenson M, Charo IF, Herndier B, Speck RF, Goldsmith MA. Progress Toward a Human CD4/CCR5 Transgenic Rat Model for De Novo Infection by Human Immunodeficiency Virus Type 1. *J Exp. Med* 2002;195:719-36.
16. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit F, Ledergerber B, Lundgren JD, Furrer H for seven European HIV Cohorts: Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. *Ann Intern Med* 2002;137:239-250.
17. Kronenberg A, Schüpbach R, Schuknecht B, Bossart W, Weber R, Gilden DH, Speck RF. Varicella zoster virus (VZV) multifocal vasculopathy: diagnostic value of serial VZV DNA analysis and intrathecal synthesis of VZV antibody in cerebrospinal fluid to corroborate clinical and neuroimaging features. *Clin Infect Dis* 2002;35:330-33.
18. Loré K, Sönnnerborg A, Broström C, Goh LE, Perrin L, McDade H, Stellbrink HJ, Gazzard B, Weber R, Napolitano LA, Kooyk Y, Andersson J. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. *AIDS* 2002;16:1-10.
19. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, d'Arminio Monforte A, Hermans P, Goebel FD, Blaxhult A, Kirk O, Phillips AN on behalf of the

- EuroSIDA Study Group: A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. *J Infect Dis* 2002;185:178-187.
20. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Gargalianos-Kakolyris P, Vella S, Lundgren JD: Association of viral load, CD4 cell count and treatment with clinical progression in HIV patients with very low CD4 cell counts: the EuroSIDA study. *J Infect Dis* 2002;186:189-197.
 21. Oehen S, Odermatt B, Karrer U, Hengartner H, Zinkernagel R, Lopez-Macias C. Marginal zone macrophages and immune responses against viruses. *J Immunol.* 2002;169:1453-8.
 22. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave J-P, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Günthard H, Howe C, Weber R, Perrin L, for the Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. *J Infect Dis* 2002;185:1251-60.
 23. Opravil M, Ledergerber B, Furrer H, Hirschel B, Imhof A, Gallant S, Wagels T, Bernasconi E, Meienberg F, Rickenbach M, Weber R, and the Swiss HIV Cohort Study. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count >350 x 10⁶/l. *AIDS* 2002;16:1371-81.
 24. Oxenius A, McLean A, Fischer M, Price DA, Dawson SJ, Hafner R, Schneider C, Joller H, Hirschel B, Phillips RE, Weber R, Günthard HF, for the Swiss HIV Cohort Study. HIV-specific CD8⁺ T cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. *J Virol* 2002;76:10169-10176.
 25. Oxenius A, Price DA, Günthard HF, Dawson SJ, Perrin L, Fagard C, Fischer M, Weber R, Hirschel B, McLean A, Phillips RE, for the Swiss HIV Cohort Study. Impact of structured treatment interruptions in chronic HIV-1 infection on HIV-specific cellular immunity. *Proc Nat Acad Sci* 2002;99:13747-13752.
 26. Oxenius A, Sewell AK, Dawson SJ, Günthard HF, Fischer M, Gillespie GM, Rowland-Jones, SL, Fagard C, Hirschel B, Phillips RE, Price DA, for the Swiss HIV-Cohort Study. Functional discrepancies in HIV-specific CD8⁺ T lymphocyte populations are related to plasma virus load. *J Clin Immunol* 2002;22(6):363-374.
 27. Oxenius A, Price DA, Dawson S, Günthard HF, Fischer M, Fagard C, Hirschel B, McLean A, Phillips R, for the Swiss HIV-Cohort Study. Functional HIV-specific CD8⁺ T cells: correlates of plasma virus load. *AIDS.* 2002;16:2317-2322.
 28. Sax H, Pittet D, and the Swiss-NOSO network. Interhospital differences in nosocomial infection rates-importance of case-mix adjustment. *Arch Intern Med* 2002;162:2437-2442.
 29. Taffé P, Rickenbach M, Hirschel B, Opravil M, Furrer H, Janin P, Bugnon B, Ledergerber B, Wagels T, Sudre P and the Swiss HIV Cohort Study. Impact of

occasional short interruptions of HAART on the progression of HIV infection: Results from a cohort study. *AIDS* 2002;16:747-755.

30. Trkola A, Kuhmann SE, Stritzki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani, A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP. HIV-1 escape from small molecule, CCR5-specific entry inhibitors in vitro does not involve CXCR4 use. *Proc Natl Acad Sci U S A.* 2002;99: 395-400.
31. Vogt PR, Brunner-LaRocca H-P, Lachat M, Ruef C, Turin MI. Technical details with the use of cryopreserved arterial allografts for aortic infection: Influence on early and mid-term mortality. *J Vasc Surg* 2002;35:80-86.
32. Wolf K*, Tsakiris DA* (*contributed equally to this work), Weber R, Erb P, Battegay M, for the Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in Human Immunodeficiency Virus (HIV)-1 infected patients. *J Infect Dis* 2002;185:456-462.

Originalpublikationen im Rahmen der Schweizerischen HIV Kohortenstudie oder anderer Studiengruppen

1. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T, and the Swiss Mother + Child HIV Cohort Study. Transplacental passage of protease inhibitors at delivery. *AIDS* 2002;16:889-893.
2. Vanhems Ph, Caillat-Vallet E, Hirschel B, Routy JP, Carr A, Vizzard J, Cooper DA, Perrin L, and The Swiss HIV Cohort Study. The CD4 cell count 3 months after acute retroviral syndrome is associated with the presence of AIDS in the source individual. *AIDS* 2002;16:2234-2236.

Übersichtsartikel (Reviews)

3. Kubli M., Kronenberg A., Himmelmann A. Hyper-IgE Syndrom: Seltene Ursache der Staphylokokkenpneumonie. *Schweiz Med Forum* 2002;27: 668-70.
4. Mathis A, Deplazes P, Weber R. Mikrosporidien: intrazelluläre Eukaryoten und opportunistische Krankheitserreger. *Denisia* 6. 2002;184:265-70.
5. Ruef C. Bedeutung der Antibiotikaresistenz bei der Behandlung von Weichteilinfektionen. *Ther Umsch* 2002;59:41-45.
6. Ruef C, Troillet N. Maladie de Creutzfeldt-Jakob: risk de transmission nosocomiale en Suisse, en 2002. *Médecine & Hygiène* 2002;60:1853-1858.

Bücher und Buchbeiträge

7. Weber R. Treatment of microsporidial infections, p.1585-1593. In: Yu V, Weber R, Raoult D (eds.) *Antimicrobial Therapy and Vaccines, Volume I: Microbes.* Apple Trees Productions, New York 2002.
8. Yu V, Weber R, Raoult D (eds.): *Antimicrobial Therapy and Vaccines. Volume I: Microbes.* Apple Trees Productions, New York 2002.

Andere Publikationen

9. Desgrandchamps D, Flepp M., Meister T. (2002) Sanford 2002/03. Leitfaden der antimikrobiellen Behandlung. 5. Adaptierte Version für die Schweiz. Übersetzung und Adaptation von: Gilbert D.N., Moellering R.C. Jr., Sande M.A. Guide to Antimicrobial Therapy 2002, Hyde Park, USA.

Dissertationen

1. Huber E. Gründe für die ausbleibende Hepatitis C-Behandlung bei Drogenabhängigen in Opiatsubstitution. Med Diss Zürich 2002.